Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Linden; Joel M.
Address:
Charlottesville, VA
No. of patents:
29
Patents:












Patent Number Title Of Patent Date Issued
8193200 Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease June 5, 2012
The present invention relates to method for treating inflammatory bowel disease that includes administration of an effective amount of an antagonist of A.sub.2B adenosine receptors (ARs).
8188063 Use of adenosine A.sub.2A modulators to treat spinal cord injury May 29, 2012
The present invention is a method for treatment or prevention of injury to nerve cells. The method can use at least one A.sub.2A receptor modulator to prevent injury to or enhance the healing of the injured cells.
8178509 Method to treat sickle cell disease May 15, 2012
The present invention provides a therapeutic method for treating an inflammatory response caused by a sickle cell crisis, comprising administration of an effective amount of an A.sub.2A adenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibi
8158604 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof April 17, 2012
The invention provides compounds having the following general formula (I): ##STR00001## wherein X, R.sup.1, R.sup.2, R.sup.7 and Z are as described here.
7989431 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity August 2, 2011
The invention provides compounds having the following general formula (I): ##STR00001## wherein X, R.sup.1, R.sup.2, R.sup.7 and Z are as described herein.
7875595 2-polycyclic propynyl adenosine analogs having A2A agonist activity January 25, 2011
The invention provides compounds having the following general formula (I): ##STR00001## wherein X, R.sup.1, R.sup.2, R.sup.7 and Z are as described herein.
7737127 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof June 15, 2010
The invention provides compounds having the following general formula (I): ##STR00001## wherein X, R.sup.1, R.sup.2, R.sup.7 and Z are as described here.
7605143 2-propynyl adenosine analogs with modified 5'-ribose groups having A.sub.2A agonist activity October 20, 2009
The invention provides compounds having the following general formula (I): ##STR00001## wherein X, R.sup.1, R.sup.2, R.sup.7 and Z are as described herein.
7576069 2-polycyclic propynyl adenosine analogs having A2A agonist activity August 18, 2009
The invention provides compounds having the following general formula (I): ##STR00001## wherein X, R.sup.1, R.sup.2, R.sup.7 and Z are as described herein.
7442687 2-polycyclic propynyl adenosine analogs having A2A agonist activity October 28, 2008
The invention provides compounds having the following general formula (I): ##STR00001## wherein X, R.sup.1, R.sup.2, R.sup.7 and Z are as described herein.
7427606 Method to reduce inflammatory response in transplanted tissue September 23, 2008
The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or antiviral agent in conjunction with an A.sub.2A adenosine receptor agonist. If no anti-path
7396825 Agonists of A2A adenosine receptors for treatment of diabetic nephropathy July 8, 2008
The present invention provides a therapeutic method for treating diabetic kidney disease, e.g., diabetic nephropathy that includes the administration of an effective amount of an A.sub.2A adenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhi
7378400 Method to reduce an inflammatory response from arthritis May 27, 2008
The present invention provides a therapeutic method for treating an inflammatory response caused by autoimmune stimulation, comprising the administration to a patient in need thereof of an antiinflammatory amount amount of an A.sub.2A adenosine receptor agonist. The autoimmune stimul
7226913 Pharmaceutical compositions having A.sub.2A adenosine receptor agonist activity June 5, 2007
The present invention provides compositions for oral administration of compounds having A.sub.2A adenosine receptor agonist activity. These compositions are useful for treatment of inflammatory conditions.
7214665 2-propynyl adenosine analogs having A.sub.2A agonist activity and compositions thereof May 8, 2007
The invention provides compounds having the following general formula (I): ##STR00001## wherein X, R.sup.1, R.sup.2, R.sup.7 and Z are as described here.
7019027 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptor March 28, 2006
The present invention relates to a compound of formula (I): ##STR00001## wherein: R.sub.3 is selected from the group consisting of 1-napthyl, 2-napthyl and cycloalkylphenyl; and R.sub.4 and R.sub.5 taken together form a ring having from 5 to 10 carbon atoms. Additionally, the inv
6713638 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptor March 30, 2004
The present invention relates to a compound of formula (I): ##STR1##wherein: R.sub.3 is selected from the group consisting of 1-napthyl, 2-napthyl and cycloalkylphenyl; and R.sub.4 and R.sub.5 taken together form a ring having from 5 to 10 carbon atoms.Additionally, the invention p
6670334 Method and compositions for treating the inflammatory response December 30, 2003
Agonists of A.sub.2A adenosine receptors optionally, in combination with a Type IV phosphodiesterase (PDE) inhibitor are effective for the inhibition of an inflammatory response in mammalian tissue, in vivo or in vitro.
6545002 Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors April 8, 2003
The present invention provides compounds having the formula I: ##STR1## X is (C.sub.1 -C.sub.8)alkylene, (C.sub.2 -C.sub.8)alkenylene, (C.sub.2 -C.sub.8)alkynylene, wherein one of the carbon atoms in the alkylene, alkenylene or alkynylene groups is optionally replaced with a group hav
6531457 Methods and compositions for treating inflammatory response March 11, 2003
Compounds and methods are provided to treat inflammatory conditions with certain A.sub.2A adenosine receptor antagonists.
6514949 Method compositions for treating the inflammatory response February 4, 2003
Agonists of A.sub.2A adenosine receptors optionally, in combination with a Type IV phosphodiesterase (PDE) inhibitor are effective for the treatment of the inflammatory response of mammalian tissue.
6448235 Method for treating restenosis with A2A adenosine receptor agonists September 10, 2002
Agonists of A.sub.2A adenosine receptors in combination with rolipram, its derivatives or other Type IV phosphodiesterase (PDE) inhibitors are effective for the treatment of restenosis.
6322771 Induction of pharmacological stress with adenosine receptor agonists November 27, 2001
A method is provided employing A.sub.2A adenosine receptor agonists as vasodilators to detect the presence and assess the severity of coronary artery stenosis.
6303619 Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors October 16, 2001
The invention concerns the use of a xanthine or a xanthine derivative having a meta-substituted acidic aryl at the 8-position to specifically modulate the physiologic role of adenosine activation of its various receptors.
6232297 Methods and compositions for treating inflammatory response May 15, 2001
Compounds and methods are provided to treat inflammatory conditions with certain A.sub.2A adenosine receptor antagonists.
6117878 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors September 12, 2000
The invention concerns the use of 8-phenylxanthines, 8-cyloalkylxanthines or 8- substituted xanthine derivatives to specifically modulate the physiologic role of the A2B adenosine receptor.
6060481 Method for improving insulin sensitivity using an adenosine receptor antagonist May 9, 2000
Methods for improving insulin sensitivity in a patient using one or more A.sub.2B adenosine receptor antagonists are disclosed. These methods stimulate insulin dependent glucose uptake in muscle.
5877180 Method for treating inflammatory diseases with A.sub.2a adenosine receptor agonists March 2, 1999
Agonists of A.sub.2a adenosine receptors are effective for the treatment of inflammatory diseases.
4376125 Aminobenzlpropranolol and pharmaceutical preparation thereof March 8, 1983
1-(p-Amino-.alpha.,.alpha.-dimethylphenethylamino)-3-(1-naphthoxy)-2-propan ol, 1-(p-hydroxy-.alpha.,.alpha.-dimethylphenethylamino)-3-(1-naphthoxy)-2-pro panol, 1-(p-methyl-.alpha.,.alpha.-dimethylphenethylamino)-3-(1-naphthoxy)-2-prop anol, 1-(p-methoxy-.alpha.,.alpha.-dimethy










 
 
  Recently Added Patents
Method of treating lung cancer
Headset electronics
Vehicle display system or projection display for a motor vehicle, and calibration method
Method of motion correction in optical coherence tomography imaging
Apparatus and method for connection control with media negotiation successful on different media formats
Power device and method of packaging same
Sporting goal practice screen
  Randomly Featured Patents
Cable connection
Lost article tracking system
Knife and chopper board combination
Method and system for intra-row, inter-row compression and decompression of data items in a database using a page-based structure where allocating a page-buffer based on a stored value indicat
Method and apparatus for scheduling and modulation and coding selection for supporting quality of service in transmission on forward shared radio channels
Method of and apparatus for stamping out sheet material blanks
Call registration and acknowledgement system for an elevator and method of testing such system
Motion compensated de-interlacing
Multiphase structured polymer particles, method of manufacturing same, and uses thereof
Flow control for low bitrate users on high-speed downlink